Repare Therapeutics (NASDAQ:RPTX) Shares Up 0.6% - Time to Buy?

Key Points

• Repare Therapeutics shares rose 0.6% to $1.56, with a market cap of $66.91 million and significant decreases in trading volume, down 87% from the average.
• Institutional investors have shown increased interest, with JPMorgan Chase & Co. raising its holdings by an extraordinary 2,144,950.0% during the 4th quarter.
• Repare Therapeutics specializes in precision oncology, focusing on therapies related to genomic instability using its proprietary SNIPRx platform.

Shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) rose 0.6% during mid-day trading on Friday . The stock traded as high as $1.58 and last traded at $1.56. Approximately 93,584 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 712,733 shares. The stock had previously closed at $1.55.

Repare Therapeutics Price Performance

The company has a market capitalization of $66.91 million, a PE ratio of -0.52 and a beta of 0.84. The stock's 50 day simple moving average is $1.44 and its 200-day simple moving average is $1.28.

Institutional Investors Weigh In On Repare Therapeutics

Several large investors have recently added to or reduced their stakes in RPTX. Acadian Asset Management LLC increased its stake in Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock worth $624,000 after buying an additional 168,230 shares during the period. Affinity Asset Advisors LLC increased its position in shares of Repare Therapeutics by 100.0% during the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock worth $197,000 after acquiring an additional 100,000 shares during the period. JPMorgan Chase & Co. increased its position in shares of Repare Therapeutics by 2,144,950.0% during the fourth quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock worth $112,000 after acquiring an additional 85,798 shares during the period. Lynx1 Capital Management LP purchased a new stake in shares of Repare Therapeutics during the fourth quarter worth $104,000. Finally, Blue Owl Capital Holdings LP increased its holdings in Repare Therapeutics by 2.1% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,443,659 shares of the company's stock worth $4,511,000 after purchasing an additional 71,160 shares during the period. 85.09% of the stock is owned by hedge funds and other institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.